XBiotech Inc
Research XBiotech Inc (XBIT) on Bullrun: market cap USD 70.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXBIT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 70.12M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.51M
- Free cash flow-USD 8.97M
Valuation Snapshot
latest market cap is USD 70.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 45.54M | -USD 40.21M | n/a | -1.49 | USD 125.55M | n/a | USD 140.35M |
| FY2024 | USD 0 | -USD 38.53M | -USD 32.27M | n/a | -1.26 | USD 172.68M | USD 10.25M | USD 182.27M |
| FY2023 | USD 0 | -USD 24.56M | -USD 19.09M | n/a | -0.81 | USD 200.02M | n/a | USD 218.85M |
| FY2022 | USD 4.01M | -USD 32.90M | -USD 15.41M | 83.8% | -1.08 | USD 157.31M | n/a | USD 240.40M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 70.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 72.87M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 120.43M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 121.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 106.84M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 338.79M | n/a | 22.5% | 2.5 |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is XBiotech Inc's market cap?
XBiotech Inc's market capitalization is USD 70.12M.
What does XBiotech Inc do?
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.